SCHEMBL2902684

SCHEMBL2902684

COCCCNc1nc(C(F)(F)F)ncc1C(=O)N1CCC(N)CC1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MERTK Q12866 5/20 0.49
REN P00797 3/20 0.44
SYK P43405 2/20 0.42
JAK3 P52333 2/20 0.40
PDE4B Q07343 3/20 0.38
TYRO3 Q06418 2/20 0.38
GAS6 Q14393 1/20 0.38
FOS P01100 2/20 0.37
JUN P05412 2/20 0.37
NFKB1 P19838 2/20 0.37
NFKB2 Q00653 2/20 0.37
RELA Q04206 2/20 0.37
LRRK2 Q5S007 1/20 0.36
RORC P51449 1/20 0.36
JAK2 O60674 1/20 0.36
JAK1 P23458 1/20 0.36
TYK2 P29597 1/20 0.36
AXL P30530 1/20 0.36
SCN9A Q15858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2902620 0.89 MERTK (0.60) MERTKRENSYKTYRO3GAS6
SCHEMBL2900049 0.87 MERTK (0.47) MERTKRENJAK3PDE4BFOS
SCHEMBL2901084 0.84 MERTK (0.49) MERTKRENSYKJAK3TYRO3
SCHEMBL2902606 0.79 REN (0.46) MERTKRENSYKJAK3PDE4B
SCHEMBL2902710 0.77 PDE8B (0.46) MERTKJAK3JAK2JAK1
SCHEMBL2897413 0.73 MERTK (0.61) MERTKSYKTYRO3GAS6AXL
SCHEMBL2898749 0.70 MERTK (0.47) MERTKRENSYKJAK3LRRK2
SCHEMBL13295728 0.69 REN (0.53) MERTKRENSYKJAK3TYRO3
SCHEMBL2899545 0.69 REN (0.54) MERTKRENSYKJAK3TYRO3
SCHEMBL2902623 0.69 REN (0.55) MERTKREN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2202228-B1 AMIDE COMPOUNDS AND USE OF THE SAME TAKEDA PHARMACEUTICAL (JP) 2014-12-10 EP disclosed
US-8329691-B2 Amide compounds and use of the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-12-11 US disclosed
US-8329691-B2 Amide compounds and use of the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-12-11 US disclosed
US-8329691-B2 Amide compounds and use of the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-12-11 US disclosed
US-20100324010-A1 AMIDE COMPOUNDS AND USE OF THE SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-23 US disclosed
US-20100324010-A1 AMIDE COMPOUNDS AND USE OF THE SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-23 US disclosed
US-20100324010-A1 AMIDE COMPOUNDS AND USE OF THE SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-23 US disclosed
EP-2202228-A1 AMIDE COMPOUNDS AND USE OF THE SAME Takeda Pharmaceutical Company Limited (JP) 2010-06-30 EP disclosed
EP-2202228-A1 AMIDE COMPOUNDS AND USE OF THE SAME Takeda Pharmaceutical Company Limited (JP) 2010-06-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324010-A1 AMIDE COMPOUNDS AND USE OF THE SAME REN, ACE, AGT MERTK 3317/4885REN 1/4885SYK 2977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.